CA2826765C - Methods and compositions for improving cognitive function - Google Patents

Methods and compositions for improving cognitive function Download PDF

Info

Publication number
CA2826765C
CA2826765C CA2826765A CA2826765A CA2826765C CA 2826765 C CA2826765 C CA 2826765C CA 2826765 A CA2826765 A CA 2826765A CA 2826765 A CA2826765 A CA 2826765A CA 2826765 C CA2826765 C CA 2826765C
Authority
CA
Canada
Prior art keywords
cognitive impairment
oxo
hydrogen
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2826765A
Other languages
English (en)
French (fr)
Other versions
CA2826765A1 (en
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2826765A1 publication Critical patent/CA2826765A1/en
Application granted granted Critical
Publication of CA2826765C publication Critical patent/CA2826765C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA2826765A 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function Active CA2826765C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441251P 2011-02-09 2011-02-09
US61/441,251 2011-02-09
PCT/US2012/024556 WO2012109491A1 (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
CA2826765A1 CA2826765A1 (en) 2012-08-16
CA2826765C true CA2826765C (en) 2021-04-06

Family

ID=46638963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2826765A Active CA2826765C (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Country Status (9)

Country Link
US (2) US20120214859A1 (enExample)
EP (2) EP2672822A4 (enExample)
JP (7) JP2014505108A (enExample)
CN (2) CN103476255A (enExample)
AU (6) AU2012214303A1 (enExample)
BR (1) BR112013020283A2 (enExample)
CA (1) CA2826765C (enExample)
RU (1) RU2665021C2 (enExample)
WO (1) WO2012109491A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078568A1 (en) * 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US20160030391A1 (en) * 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
EP4499154A1 (en) 2022-03-25 2025-02-05 REGENXBIO Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN115517682B (zh) * 2022-11-25 2023-01-31 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
MXPA05012538A (es) * 2003-05-23 2006-02-22 Otsuka Pharma Co Ltd Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
HRP20141185T1 (hr) * 2005-07-26 2015-01-30 Ucb Pharma Sa Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
AU2009279372A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
EP3260118B1 (en) * 2008-10-16 2021-03-24 The Johns Hopkins University Methods and compositions for improving cognitive function
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN101647789B (zh) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
US20110212928A1 (en) * 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function

Also Published As

Publication number Publication date
JP2021175759A (ja) 2021-11-04
JP2016172772A (ja) 2016-09-29
US20230033195A1 (en) 2023-02-02
AU2021200325B2 (en) 2022-07-28
US20120214859A1 (en) 2012-08-23
JP2014505108A (ja) 2014-02-27
AU2019268069A1 (en) 2019-12-12
CA2826765A1 (en) 2012-08-16
JP2025109773A (ja) 2025-07-25
BR112013020283A2 (pt) 2016-07-19
CN109662961A (zh) 2019-04-23
RU2013141155A (ru) 2015-03-20
AU2022221492A1 (en) 2022-09-22
JP2023126654A (ja) 2023-09-07
EP2672822A1 (en) 2013-12-18
EP3400934A1 (en) 2018-11-14
WO2012109491A1 (en) 2012-08-16
AU2021200325A1 (en) 2021-03-18
AU2016202670A1 (en) 2016-05-19
AU2012214303A1 (en) 2013-09-12
RU2665021C2 (ru) 2018-08-24
RU2018129580A3 (enExample) 2022-03-25
RU2018129580A (ru) 2019-03-20
AU2018201303A1 (en) 2018-03-15
CN103476255A (zh) 2013-12-25
EP2672822A4 (en) 2014-08-27
JP2018100305A (ja) 2018-06-28
JP2020079318A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
AU2021200325B2 (en) Methods and compositions for improving cognitive function
US20230277501A1 (en) Methods and compositions for improving cognitive function
CA2891122C (en) Methods and compositions for treating schizophrenia
CA2789014C (en) Methods and compositions for improving cognitive function
CA2904767C (en) Methods and compositions for improving cognitive function
US20160030391A1 (en) Methods and compositions for improving cognitive function
AU2018208662B2 (en) Methods and Compositions for Treating Schizophrenia
HK1261244A1 (en) Levetiracetam for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK40003608A (en) Methods and compositions for improving cognitive function
HK40021943A (en) Methods and compositions for treating schizophrenia
HK1192821A (en) Methods and compositions for improving cognitive function
AU2013344646A1 (en) Methods and compositions for treating schizophrenia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170202